Prescribing by Numbers - Drugs and the Definition of Disease (Paperback)


The second half of the twentieth century witnessed the emergence of a new model of chronic disease -- diagnosed on the basis of numerical deviations rather than symptoms and treated on a preventive basis before any overt signs of illness develop -- that arose in concert with a set of safe, effective, and highly marketable prescription drugs. Physician-historian Jeremy A. Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical marketing, and he explores how this interaction has profoundly altered the experience, politics, ethics, and economy of health in late-twentieth-century America. His provocative analysis sheds light on the increasing presence of the subjectively healthy but highly medicated individual in the American medical landscape, suggesting how historical perspective can help to address the problems inherent in the program of pharmaceutical prevention.

"Greene describes the relationship between advances in treatment, the incentives of manufacturers, and the effect on the public of increased attention to prevention... The risk-benefit trade-offs of the quantitative approach are complex, and Greene's historical revelations are timely." -- New England Journal of Medicine

"One of the best, and most significant, books published recently on the development of medical practice and the pharmaceutical industry in the U.S. in the second half of the twentieth century." -- Social History of Medicine

"Greene focuses on the question of how public health priorities became closely aligned with the pharmaceutical industry's marketing practices... [and] offers a nuanced descriptionof the development of 'therapeutics of risk reduction' with multiple lines of influence, subtle power shifts, and gains and losses for patients and physicians." -- Chemical Heritage

"A gripping story... Greene warns us in his superb book that things are not always as they are claimed." -- Yale Journal for Humanities in Medicine

Jeremy A. Greene is a fellow in the Department of Social Medicine at Harvard Medical School and a resident in the Department of Medicine at Brigham and Women's Hospital.


R750

Or split into 4x interest-free payments of 25% on orders over R50
Learn more

Discovery Miles7500
Mobicred@R70pm x 12* Mobicred Info
Free Delivery
Delivery AdviceShips in 12 - 17 working days


Toggle WishListAdd to wish list
Review this Item

Product Description

The second half of the twentieth century witnessed the emergence of a new model of chronic disease -- diagnosed on the basis of numerical deviations rather than symptoms and treated on a preventive basis before any overt signs of illness develop -- that arose in concert with a set of safe, effective, and highly marketable prescription drugs. Physician-historian Jeremy A. Greene examines the mechanisms by which drugs and chronic disease categories define one another within medical research, clinical practice, and pharmaceutical marketing, and he explores how this interaction has profoundly altered the experience, politics, ethics, and economy of health in late-twentieth-century America. His provocative analysis sheds light on the increasing presence of the subjectively healthy but highly medicated individual in the American medical landscape, suggesting how historical perspective can help to address the problems inherent in the program of pharmaceutical prevention.

"Greene describes the relationship between advances in treatment, the incentives of manufacturers, and the effect on the public of increased attention to prevention... The risk-benefit trade-offs of the quantitative approach are complex, and Greene's historical revelations are timely." -- New England Journal of Medicine

"One of the best, and most significant, books published recently on the development of medical practice and the pharmaceutical industry in the U.S. in the second half of the twentieth century." -- Social History of Medicine

"Greene focuses on the question of how public health priorities became closely aligned with the pharmaceutical industry's marketing practices... [and] offers a nuanced descriptionof the development of 'therapeutics of risk reduction' with multiple lines of influence, subtle power shifts, and gains and losses for patients and physicians." -- Chemical Heritage

"A gripping story... Greene warns us in his superb book that things are not always as they are claimed." -- Yale Journal for Humanities in Medicine

Jeremy A. Greene is a fellow in the Department of Social Medicine at Harvard Medical School and a resident in the Department of Medicine at Brigham and Women's Hospital.

Customer Reviews

No reviews or ratings yet - be the first to create one!

Product Details

General

Imprint

Johns Hopkins University Press

Country of origin

United States

Release date

February 2009

Availability

Expected to ship within 12 - 17 working days

First published

2007

Authors

Dimensions

229 x 152 x 22mm (L x W x T)

Format

Paperback

Pages

336

ISBN-13

978-0-8018-9100-7

Barcode

9780801891007

Categories

LSN

0-8018-9100-0



Trending On Loot